María T. Bourlon

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 307 citations · Full text

Medicine, Oncology, Pharmacology +10

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · Annals of Oncology · 2020 · 116 citations · Full text

Medicine, Oncology, Pharmacology +11

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen, Fabio Turco, Ian D. Davis et al. · European Urology · 2024 · 115 citations · Full text

Medicine, Oncology, Urology +9

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

Alexandra S. Rashedi, Saskia F. de Roo, Lauren Ataman et al. · JCO Global Oncology · 2017 · 99 citations · Full text

Medicine, Health Policy, Oncology +13